| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Restoret | EYE103; EYE-103; MK-3000; ANT-39 | Phase 3 Clinical | Diabetic macular oedema; Macular Degeneration | Details | |
| BI-905681 | BI-905681 | Phase 1 Clinical | Boehringer Ingelheim Ltd | Neoplasms | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



